Ramandip Grewal

Adjunct Scientist (Full Status) ICES Central Populations & Public Health Research Program

PhD, Epidemiology, University of Toronto
MPH, Epidemiology, University of Toronto
BSc, Health Studies, University of Waterloo

Public health
Immunizations
Infectious diseases
Health services research

Scientist, Public Health Ontario
Assistant Professor, Centre for Vaccine Preventable Diseases, Dalla Lana School of Public Health, University of Toronto

ICES Grants

Grant

2025 - 2026

Real-world effectiveness of 2 doses of Imvamune® and duration of protection

Granting Agency: Canadian Immunization Research Network (CIRN)
Principal Investigators: Navarro C
Co-Investigators: Zygmunt A, Grewal R, Tan D, Burchell A, Hasso M, Grennan T, Mishra S, Friedman L, Nasreen S, Austin P, Brouseau N
Grant Type: Operating
Grant Amount: $50,033

See All

Journal Articles

Journal Article

26/11/2025

Characteristics of individuals who received a complete, 2-dose mpox vaccine regimen as part of the public health response to the mpox epidemic in Ontario, Canada

Grewal R, Lau C, Kwong JC, Burchell AN, Friedman L, Navarro C, Okpokoro E, Tan DHS, Zygmunt A, Bai L, Mishra S, Buchan SA; Canadian Immunization Research Network (CIRN) Investigators. PLOS Glob Public Health. 2025; 5(11):e0005452.

Journal Article

26/05/2025

Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada

Lee N, Nguyen L, Nasreen S, Austin PC, Brown KA, Buchan SA, Grewal R, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC; Canadian Immunization Research Network (CIRN) Investigators. Vaccine. 2025; May 26 [Epub ahead of print].

Journal Article

24/11/2023

Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults

Lee N, Nguyen L, Austin PC, Brown KA, Grewal R, Buchan SA, Nasreen S, Gubbay J, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC. Clin Infect Dis. 2024; Nov 24 {Epub ahead of print].

Journal Article

05/10/2023

Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study

Grewal R, Buchan SA, Nguyen L, Nasreen S, Austin PC, Brown KA, Gubbay J, Lee N, Schwartz KL, Tadrous M, Wilson K, Wilson SE, Kwong JC. J Infect Dis. 2023; Oct 5 [Epub ahead of print].

Journal Article

07/03/2023

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Grewal R, Nguyen L, Buchan SA, Wilson SE, Nasreen S, Austin PC, Brown KA, Fell DB, Gubbay JB, Schwartz KL, Tadrous M, Wilson K, Kwong JC. Nat Commun. 2023; 14(1):1273. Epub 2023 Mar 7.

Journal Article

03/12/2022

Effectiveness and duration of protection of a fourth dose of Coronavirus disease 2019 messenger RNA vaccine among long-term care residents in Ontario, Canada

Grewal R, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. J Infect Dis. 2023; 227(8):977–80. Epub 2022 Dec 3.

Journal Article

06/07/2022

Effectiveness of a fourth dose of COVID-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study

Grewal R, Kitchen SA, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. BMJ. 2022; 378:e071502. Epub 2022 Jul 6.

See All

Contact Details

Get in touch with
Ramandip Grewal

"*" indicates required fields

Ramandip Grewal

Education

Research Focus

Other Affiliations

ICES Grants

Real-world effectiveness of 2 doses of Imvamune® and duration of protection

Journal Articles

Characteristics of individuals who received a complete, 2-dose mpox vaccine regimen as part of the public health response to the mpox epidemic in Ontario, Canada

Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada

Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults

Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Effectiveness and duration of protection of a fourth dose of Coronavirus disease 2019 messenger RNA vaccine among long-term care residents in Ontario, Canada

Effectiveness of a fourth dose of COVID-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study

Get in touch with
Ramandip Grewal

Ramandip Grewal

Education

Research Focus

Other Affiliations

ICES Grants

Real-world effectiveness of 2 doses of Imvamune® and duration of protection

Journal Articles

Characteristics of individuals who received a complete, 2-dose mpox vaccine regimen as part of the public health response to the mpox epidemic in Ontario, Canada

Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada

Protection conferred by COVID-19 vaccination, prior SARS-CoV-2 infection, or hybrid immunity against Omicron-associated severe outcomes among community-dwelling adults

Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged ≥50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Effectiveness and duration of protection of a fourth dose of Coronavirus disease 2019 messenger RNA vaccine among long-term care residents in Ontario, Canada

Effectiveness of a fourth dose of COVID-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study

Get in touch with Ramandip Grewal

Get in touch with
Ramandip Grewal